Bulletin
Investor Alert

New York Markets Close in:

Caribou Biosciences Inc.

NAS: CRBU

GO
/marketstate/country/us

Market open

 --Real time quotes

Feb 1, 2023, 1:10 p.m.

/zigman2/quotes/228313444/composite

$

7.19

Change

-0.02 -0.28%

Volume

Volume 157,424

Real time quotes

/zigman2/quotes/228313444/composite

Previous close

$ 7.21

$ 7.19

Change

-0.02 -0.28%

Day low

Day high

$6.92

$7.28

Open

52 week low

52 week high

$4.89

$13.19

Open

Company Description

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial ...

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Valuation

Price to Sales Ratio

94.75

Price to Book Ratio

2.34

Enterprise Value to EBITDA

-0.90

Enterprise Value to Sales

4.67

Efficiency

Total Asset Turnover

0.04

Liquidity

Current Ratio

15.15

Quick Ratio

15.15

Cash Ratio

14.55

Profitability

Gross Margin

89.75

Operating Margin

-697.84

Pretax Margin

-693.92

Net Margin

-697.26

Return on Assets

-27.67

Return on Equity

-36.73

Return on Total Capital

-32.85

Capital Structure

Total Debt to Total Assets

0.06

Officers and Executives

Name Age Officer Since Title
Dr. Rachel E. Haurwitz 35 2011 Founder
Mr. Jason O’Byrne - 2021 Chief Financial Officer
Dr. Steven B. Kanner 61 2017 Chief Scientific Officer
Ms. Cherry T. Thomas - - Senior Vice President-Clinical Development
Dr. Syed Rizvi - 2022 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/02/2022 Steven B. Kanner
Chief Scientific Officer
21,401   Derivative/Non-derivative trans. at $2.69 per share. 57,568
10/06/2022 Ryan Fischesser
VP of Finance and Controller
2,839   Derivative/Non-derivative trans. at $4.11 per share. 11,668
10/06/2022 Ryan Fischesser
VP of Finance and Controller
2,839   Derivative/Non-derivative trans. at $2.69 per share. 7,636
10/06/2022 Ryan Fischesser
VP of Finance and Controller
10,000   Disposition at $10.8 per share. 108,000
09/15/2022 Barbara G. McClung
Chief Legal Officer
27,518   Derivative/Non-derivative trans. at $2.69 per share. 74,023
09/15/2022 Barbara G. McClung
Chief Legal Officer
77   Derivative/Non-derivative trans. at $2.69 per share. 207
08/25/2022 Steven B. Kanner
Chief Scientific Officer
43,248   Disposition at $11.22 per share. 485,242
08/25/2022 Steven B. Kanner
Chief Scientific Officer
43,248   Derivative/Non-derivative trans. at $2.69 per share. 116,337
08/22/2022 Ryan Fischesser
VP of Finance and Controller
4,848   Award at $0 per share. 0
05/13/2022 Steven B. Kanner
Chief Scientific Officer
6,114   Derivative/Non-derivative trans. at $2.69 per share. 16,446
05/13/2022 Steven B. Kanner
Chief Scientific Officer
68,306   Derivative/Non-derivative trans. at $1.81 per share. 123,633
05/09/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/04/2022 Steven B. Kanner
Chief Scientific Officer
1,549   Derivative/Non-derivative trans. at $4.11 per share. 6,366
03/04/2022 Steven B. Kanner
Chief Scientific Officer
9,171   Derivative/Non-derivative trans. at $2.69 per share. 24,669
/news/latest/company/us/crbu

MarketWatch News on CRBU

  1. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    3:25 p.m. June 23, 2022

    - Barron's Online

  2. These 3 Funds Invest Like ARK But Didn’t Fall as Far

    11:32 p.m. Feb. 11, 2022

    - Barron's Online

  3. Caribou Biosciences started at outperform with $36 stock price target at Oppenheimer

    7:34 a.m. Dec. 1, 2021

    - Tomi Kilgore

  4. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  5. Caribou Biosciences started at buy with $30 stock price target at BofA Securities

    9:23 a.m. Aug. 17, 2021

    - Tomi Kilgore

  6. 7 Companies Open for Trading. Here's How They Did.

    3:58 p.m. July 23, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/crbu

Other News on CRBU

  1. Tradeweb Exchange-Traded Funds Update - September 2022

    12:17 p.m. Oct. 14, 2022

    - Seeking Alpha

  2. Caribou Biosciences (CRBU) Investor Presentation - Slideshow

    8:44 a.m. Sept. 14, 2022

    - Seeking Alpha

  3. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    5:39 p.m. Aug. 17, 2022

    - Seeking Alpha

  4. Caribou Biosciences: Potential To Change CAR-T Landscape

    1:19 p.m. Aug. 1, 2022

    - Seeking Alpha

  5. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    5:18 p.m. June 10, 2022

    - Seeking Alpha

  6. HYMC, AXLA and EVLO among mid-day gainers

    11:49 a.m. June 10, 2022

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Caribou Biosciences, Inc.

2929 7th Street

Suite 105

Berkeley, California 94710

Phone

1 5109826030

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$9.60M

Net Income

$-66.92M

Employees

99.00

/news/pressrelease/company/us/crbu

Press Releases on CRBU

  1. Loading more headlines...
Link to MarketWatch's Slice.